Cochrane · systematic review · CD010069
Interventions for tophi in gout
Sriranganathan, MK, Vinik, O, Pardo Pardo, J, et al. · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
24
current version
GRADE rated
16
No studies
8
Included studies
NR
No studies 8 · 33.3%Ungraded 0 · 0%Very low 0 · 0%Low 8 · 33.3%Moderate 8 · 33.3%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyPegloticase every two weeks (biweekly) compared with placebo for tophi in gout
Population: participants with tophi in gout
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Proportion with complete resolution of tophi Pegloticase every two weeks (biweekly) vs placebo | RR 5.45 [1.38, 21.54] | 1 study · 79 participants | Moderate Downgraded: imprecision |
Joint pain reduction ‐ not reported Pegloticase every two weeks (biweekly) vs placebo | no estimate extracted | NR | No studies |
Quality of life ‐ not reported Pegloticase every two weeks (biweekly) vs placebo | no estimate extracted | NR | No studies |
Serum urate normalisation ‐ not reported Pegloticase every two weeks (biweekly) vs placebo | no estimate extracted | NR | No studies |
Function ‐ not reported Pegloticase every two weeks (biweekly) vs placebo | no estimate extracted | NR | No studies |
Number of participant withdrawals due to adverse events Pegloticase every two weeks (biweekly) vs placebo | RR 7.59 [1.04, 55.55] | 1 study · 128 participants | Moderate Downgraded: imprecision |
Total adverse events Pegloticase every two weeks (biweekly) vs placebo | RR 0.99 [0.91, 1.07] | 1 study · 128 participants | Moderate Downgraded: imprecision |
Monthly pegloticase compared with placebo for tophi in gout
Population: participants with tophi in gout
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Proportion with complete resolution of tophi Monthly pegloticase vs placebo | RR 2.86 [0.68, 11.97] | 1 study · 79 participants | Moderate Downgraded: imprecision |
Joint pain reduction ‐ not reported Monthly pegloticase vs placebo | no estimate extracted | NR | No studies |
Quality of life ‐ not reported Monthly pegloticase vs placebo | no estimate extracted | NR | No studies |
Serum urate normalisation ‐ not reported Monthly pegloticase vs placebo | no estimate extracted | NR | No studies |
Function ‐ not reported Monthly pegloticase vs placebo | no estimate extracted | NR | No studies |
Number of participant withdrawals due to adverse events Monthly pegloticase vs placebo | RR 8.19 [1.12, 59.71] | 1 study · 127 participants | Moderate Downgraded: imprecision |
Total adverse events Monthly pegloticase vs placebo | RR 1.05 [0.98, 1.14] | 1 study · 127 participants | Moderate Downgraded: imprecision |
Lesinurad 200 mg plus allopurinol compared to placebo plus allopurinol for tophi in gout
Population: participants with tophi in gout
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Proportion with complete resolution of a target tophus Lesinurad 200 mg plus allopurinol vs placebo plus allopurinol | RR 0.4 [0.04, 4.57] | 2 studies · 103 participants | Moderate Downgraded: imprecision |
Lesinurad 400 mg plus allopurinol compared to placebo plus allopurinol for tophi in gout
Population: participants with tophi in gout
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Proportion with complete resolution of a target tophus Lesinurad 400 mg plus allopurinol vs placebo plus allopurinol | RR 0.79 [0.42, 1.49] | 2 studies · 98 participants | Moderate Downgraded: imprecision |
Lesinurad 400 mg plus febuxostat CONTINUED compared to lesinurad 200 mg plus febuxostat CONTINUED for tophi in gout
Population: participants with tophi in gout
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Proportion with complete resolution of a target tophus Lesinurad 400 mg plus febuxostat CONTINUED vs lesinurad 200 mg plus febuxostat CONTINUED | RR 1.11 [0.85, 1.46] | 1 study · 129 participants | Low Downgraded: imprecision, indirectness |
Total adverse events Lesinurad 400 mg plus febuxostat CONTINUED vs lesinurad 200 mg plus febuxostat CONTINUED | RR 1.12 [0.96, 1.32] | 1 study · 129 participants | Low Downgraded: imprecision, indirectness |
Number of participant withdrawals due to adverse events Lesinurad 400 mg plus febuxostat CONTINUED vs lesinurad 200 mg plus febuxostat CONTINUED | RR 0.98 [0.44, 2.2] | 1 study · 129 participants | Low Downgraded: imprecision, indirectness |
Mean sUA at end of 12 months Lesinurad 400 mg plus febuxostat CONTINUED vs lesinurad 200 mg plus febuxostat CONTINUED | no estimate extracted | 1 study · 129 participants | Low Downgraded: imprecision, indirectness |
Lesinurad 400 mg plus febuxostat CROSS compared to lesinurad 200 mg plus febuxostat CROSS for tophi in gout
Population: participants with tophi in gout
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Proportion with complete resolution of a target tophus Lesinurad 400 mg plus febuxostat CROSS vs lesinurad 200 mg plus febuxostat CROSS | RR 1.18 [0.7, 1.98] | 1 study · 67 participants | Low Downgraded: imprecision, indirectness |
Total adverse events Lesinurad 400 mg plus febuxostat CROSS vs lesinurad 200 mg plus febuxostat CROSS | RR 1.19 [1, 1.41] | 1 study · 67 participants | Low Downgraded: imprecision, indirectness |
Number of participant withdrawals due to adverse events Lesinurad 400 mg plus febuxostat CROSS vs lesinurad 200 mg plus febuxostat CROSS | RR 2.43 [0.51, 11.64] | 1 study · 67 participants | Low Downgraded: imprecision, indirectness |
Mean sUA at end of 12 months Lesinurad 400 mg plus febuxostat CROSS vs lesinurad 200 mg plus febuxostat CROSS | no estimate extracted | 1 study · 67 participants | Low Downgraded: imprecision, indirectness |
Pegloticase every two weeks (biweekly) compared with placebo for participants with tophi
Population: participants with tophi in gout
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Regression of tophi Central reader blinded to treatment allocation using RECIST software Pegloticase every two weeks (biweekly) vs placebo | RR 5.45 [1, 22] | 1 study · 79 participants | Moderate Downgraded: imprecision |
Joint pain reduction ‐ not reported Pegloticase every two weeks (biweekly) vs placebo | no estimate extracted | NR | No studies |
Quality of life ‐ not reported Pegloticase every two weeks (biweekly) vs placebo | no estimate extracted | NR | No studies |
Serum urate normalisation ‐ not reported Pegloticase every two weeks (biweekly) vs placebo | no estimate extracted | NR | No studies |
Function ‐ not reported Pegloticase every two weeks (biweekly) vs placebo | no estimate extracted | NR | No studies |
Number of participant withdrawals due to adverse events Participant files reviewed by committee blinded to treatment allocation Pegloticase every two weeks (biweekly) vs placebo | RR 7.59 [1.04, 55.55] | 1 study · 128 participants | Moderate Downgraded: imprecision |
Total adverse events ‐ not reported Pegloticase every two weeks (biweekly) vs placebo | RR 0.99 [0.91, 1.07] | 1 study · 128 participants | Moderate Downgraded: imprecision |
Monthly pegloticase compared with placebo for tophi
Population: participants with tophi in gout
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Regression of tophi Central reader blinded to treatment allocation with RECIST software Monthly pegloticase vs placebo | RR 2.86 [0.7, 12] | 1 study · 79 participants | Moderate Downgraded: imprecision |
Joint pain reduction ‐ not reported Monthly pegloticase vs placebo | no estimate extracted | NR | No studies |
Quality of life ‐ not reported Monthly pegloticase vs placebo | no estimate extracted | NR | No studies |
Serum urate normalisation ‐ not reported Monthly pegloticase vs placebo | no estimate extracted | NR | No studies |
Function ‐ not reported Monthly pegloticase vs placebo | no estimate extracted | NR | No studies |
Number of participant withdrawals due to adverse events Participant files reviewed by committee blinded to treatment allocation Monthly pegloticase vs placebo | RR 8.19 [1.12, 59.71] | 1 study · 127 participants | Moderate Downgraded: imprecision |
Total adverse events Monthly pegloticase vs placebo | RR 1.05 [0.98, 1.14] | 1 study · 127 participants | Moderate Downgraded: imprecision |